



February 3, 2015

Akebia to Present at the 17th Annual BIO CEO & Investor Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that John P. Butler, President and Chief Executive Officer, will present at the 17th Annual BIO CEO & Investor Conference on Tuesday, February 10, 2015, at 2:00 p.m. Eastern Time. The conference is being held at the Waldorf Astoria Hotel in New York City.

A live audio webcast of the presentation will be available on the company's website at <http://ir.akebia.com/events.cfm>. An archived presentation will be available for 90 days.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through HIF biology. Akebia's lead product candidate, AKB-6548, is a once-daily, oral therapy, which has completed a Phase 2b study for the treatment of anemia related to CKD in non-dialysis patients and is also being tested in a Phase 2 study for the treatment of anemia in patients undergoing dialysis. For more information on Akebia, please visit www.akebia.com.

Investors:

Argot Partners

Andrea Rabney, +1-212-600-1902

Andrea@argotpartners.com

or

Media:

Argot Partners

Eliza Schleifstein, +1-917-763-8106

Eliza@argotpartners.com

Source: Akebia Therapeutics, Inc.

News Provided by Acquire Media